19 Sep 2021
Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Physician’s Choice in Pre-treated Locally Advanced or Metastatic HER2-Positive Breast Cancer
Author: admintech | Filed under: Press ReleaseNIJMEGEN, Netherlands, Sept. 19, 2021 /PRNewswire/ — At a late-breaking oral presentation (LBA15) at the virtual 2021 ESMO Congress today, Byondis B.V., an independent, clinical stage biopharmaceutical company creating precision medicines, reported positive results from its pivotal Phase…